Multitarget anti-EBV therapy to prevent primary infection in kidney transplant recipients from deceased donor, at risk of post-transplantation lymphoproliferative disorder (EBV D+/R-)

Transpl Int. 2020 Sep;33(9):1144-1145. doi: 10.1111/tri.13652. Epub 2020 Jul 9.

Authors

Simon Ville^{1

2}, Jacques Dantal^{1

2}

Affiliations

¹ Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
² Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.

PMID: 32418275
DOI: 10.1111/tri.13652

No abstract available

Publication types

Letter
Comment

MeSH terms

Epstein-Barr Virus Infections*
Herpesvirus 4, Human / immunology
Humans
Kidney Transplantation* / adverse effects
Lymphoproliferative Disorders* / etiology
Lymphoproliferative Disorders* / prevention & control
Pilot Projects
Rituximab
Transplant Recipients
Viremia

Substances

Rituximab